Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Boosted by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 26.8% in the 4th quarter, Holdings Channel reports. The fund owned 51,997 shares of the biopharmaceutical company’s stock after buying an additional 11,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Intra-Cellular Therapies were worth $3,791,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ITCI. Vanguard Group Inc. grew its position in Intra-Cellular Therapies by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company’s stock valued at $444,834,000 after buying an additional 43,689 shares in the last quarter. BlackRock Inc. grew its position in Intra-Cellular Therapies by 13.1% in the 1st quarter. BlackRock Inc. now owns 6,470,417 shares of the biopharmaceutical company’s stock valued at $395,924,000 after buying an additional 748,651 shares in the last quarter. Wellington Management Group LLP bought a new position in Intra-Cellular Therapies in the 1st quarter valued at about $248,502,000. State Street Corp grew its position in Intra-Cellular Therapies by 3.9% in the 2nd quarter. State Street Corp now owns 2,105,705 shares of the biopharmaceutical company’s stock valued at $133,333,000 after buying an additional 79,477 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Intra-Cellular Therapies by 4.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after purchasing an additional 86,388 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 75,361 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $67.25, for a total transaction of $5,068,027.25. Following the transaction, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at $70,633,280.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Lawrence J. Hineline sold 13,337 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Sharon Mates sold 75,361 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $67.25, for a total transaction of $5,068,027.25. Following the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $70,633,280.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 311,765 shares of company stock valued at $20,860,487. 3.40% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $65.88 on Friday. The company has a 50 day simple moving average of $69.03 and a 200-day simple moving average of $63.32. The firm has a market capitalization of $6.38 billion, a price-to-earnings ratio of -45.12 and a beta of 1.02. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $76.11.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The business had revenue of $132.10 million during the quarter, compared to analyst estimates of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm’s revenue was up 50.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.45) earnings per share. On average, analysts predict that Intra-Cellular Therapies, Inc. will post -0.65 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ITCI shares. The Goldman Sachs Group raised their price objective on shares of Intra-Cellular Therapies from $58.00 to $64.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Mizuho raised their price objective on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Needham & Company LLC restated a “buy” rating and set a $82.00 price objective on shares of Intra-Cellular Therapies in a research report on Friday, April 5th. Finally, Bank of America upped their price objective on shares of Intra-Cellular Therapies from $74.00 to $82.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $81.42.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.